Adaptimmune Therapeutics PLC expected to post a loss of 13 cents a share - Earnings Preview

Adaptimmune Therapeutics

18/03/2025 12:58

Adaptimmune Therapeutics PLC ADAP.OQ ADAP.O is expected to show a rise in quarterly revenue when it reports  results on March 20 for the period ending December 31 2024

The Abingdon Oxfordshire-based  company is expected to report a 2,424.5% increase in revenue to $5.832 million from $231 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Adaptimmune Therapeutics PLC is for a loss of 13 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Adaptimmune Therapeutics PLC is $2.00​, above​ its last closing price of $0.46. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.12
-0.13
-0.01
Beat
92.2
Jun. 30 2024
-0.05
-0.07
0.24
Beat
434.9
Mar. 31 2024
-0.07
-0.10
-0.18
Missed
-83.7​
Dec. 31 2023
-0.08
-0.10
-0.24
Missed
-140
​​Sep. 30 2023
-0.12
-0.14
-0.20
Missed
-45.5
Jun. 30 2023
-0.12
-0.13
-0.23
Missed
-72.8​
Mar. 31 2023
-0.15
-0.15
0.01
Beat
104.1
Dec. 31 2022
-0.25
-0.25
-0.18
Beat
27.5

This summary was machine generated March 18 at 12:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)